Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
NCT07895355Phase 2Not yet recruiting
- Sponsor
- RemeGen
- Start
- Nov 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of RC148 in colorectal cancer (CRC), sponsored by RemeGen. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
RC148
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07895355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07895355.